Ultragenyx Pharmaceutical... (RARE)
37.80
-1.09 (-2.80%)
At close: Mar 28, 2025, 3:59 PM
37.70
-0.27%
After-hours: Mar 28, 2025, 07:50 PM EDT
Ultragenyx Pharmaceutical Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
| Revenue | 560.23M | 434.25M | 363.33M | 351.41M | 271.03M | 103.71M | 51.49M | 2.61M | 133K | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 76.73M | 45.21M | 28.32M | 16.01M | 6.13M | 9.01M | 1.15M | 1K | 183.2M | 1.38M | n/a | n/a | n/a | n/a |
| Gross Profit | 483.5M | 389.04M | 335.01M | 335.4M | 264.9M | 94.71M | 50.35M | 2.61M | -183.07M | -1.38M | n/a | n/a | n/a | n/a |
| Operating Income | -535.97M | -569.21M | -648.92M | -381.74M | -330.12M | -424.17M | -371.37M | -328.94M | -248.01M | -147.74M | -56.78M | -32.28M | -15.98M | -6.56M |
| Interest Income | 36.51M | 26.69M | 11.07M | 1.93M | 7.04M | 13.24M | 9.54M | 4.07M | 3.79M | 2.32M | 608K | 216K | 1K | 4K |
| Pretax Income | -567.59M | -608.46M | -701.73M | -452.98M | -185.36M | -399.44M | -197.1M | -318.34M | -245.84M | -145.62M | -59.8M | -35.07M | -16.33M | -6.85M |
| Net Income | -569.18M | -606.64M | -707.42M | -454.02M | -186.57M | -402.73M | -197.61M | -302.14M | -245.87M | -145.62M | -59.8M | -35.07M | -16.33M | -6.85M |
| Selling & General & Admin | 321.61M | 309.8M | 278.14M | 219.98M | 182.93M | 161.52M | 127.72M | 99.91M | 64.94M | 33M | 10.81M | 4.45M | 3.34M | 1.84M |
| Research & Development | 697.87M | 648.45M | 705.79M | 497.15M | 412.08M | 357.36M | 294M | 231.64M | 183.2M | 114.74M | 45.97M | 27.83M | 12.64M | 4.72M |
| Other Expenses | n/a | n/a | 9.51M | 241K | 7.64M | 12.45M | 3.95M | 10.6M | 2.17M | -200K | -3.02M | -3.01M | -350K | -22K |
| Operating Expenses | 1.02B | 958.25M | 983.93M | 717.13M | 595.02M | 518.88M | 421.72M | 331.55M | 248.14M | 147.74M | 56.78M | 32.28M | 15.98M | 6.56M |
| Interest Expense | 63.04M | 66M | 43.02M | 29.42M | 33.29M | 1.14M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 270K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 1.1B | 1B | 1.01B | 733.14M | 601.15M | 527.89M | 422.87M | 331.55M | 248.14M | 147.74M | 56.78M | 32.28M | 15.98M | 6.56M |
| Income Tax | 1.6M | -1.82M | 5.7M | 1.04M | 1.21M | 3.28M | 514K | -16.2M | 35K | -2.32M | -684K | -3.01M | -350K | 248K |
| Shares Outstanding (Basic) | 90.54M | 73.54M | 69.91M | 67.8M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 29.06M | 23.06M | 23.06M |
| Shares Outstanding (Diluted) | 90.54M | 73.54M | 69.91M | 67.8M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 29.06M | 23.06M | 23.06M |
| EPS (Basic) | -6.29 | -8.25 | -10.12 | -6.7 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.3 |
| EPS (Diluted) | -6.29 | -8.25 | -10.12 | -6.7 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.3 |
| EBITDA | -469M | -516.45M | -640.51M | -410.32M | -139.81M | -389.77M | -177.56M | -312.51M | -244.58M | -146.35M | -56.09M | -34.63M | -16.02M | -6.54M |
| Depreciation & Amortization | 35.54M | 26.01M | 18.2M | 13.24M | 12.26M | 8.54M | 19.54M | 5.83M | 3.42M | 1.38M | 684K | 444K | 313K | 34K |